Survival of patients with advanced non-small-cell lung cancer under maintenance therapy with CIMAvax-EGF or nimotuzumab

Authors

Abstract

Introduction: Two immunotherapies aimed at the epidermal growth factor receptor (EGFR) have been developed in Cuba and registered as maintenance therapy for patients with advanced non-small-cell lung cancer.

Objective: Evaluate the survival of patients with advanced non-small-cell lung cancer under treatment with CIMAvax-EGF or nimotuzumab.

Methods: An observational prospective longitudinal study was conducted from January 2017 to January 2020 at Hermanos Ameijeiras Clinical Surgical Hospital. The sample was composed of 77 patients divided in two groups: CIMAvax-EGF (31 patients) and nimotuzumab (46 patients). An evaluation was performed of overall survival, disease-free survival and toxicity. The Cox logistic regression was applied and a forest plot was developed. The RevMan 5.0 system was used.

Results: Both treatment groups exhibited a predominance of patients aged over 65 years, white skin color, a good general state and adenocarcinoma. Overall and progression-free survival was 18.0 and 7.2 months. In the vaccine group it was higher in patients receiving nimotuzumab, with 11.3 and 5.3 months, respectively. The most common toxicities in immunized patients were injection site pain, fever and headache in the vaccine group, and fatigue, nausea and vomiting in the nimotuzumab group.

Conclusions: Patients under maintenance therapy with the CIMAvax-EGF vaccine had a higher overall and progression-free survival than patients treated with nimotuzumab.

Key words: survival, lung cancer, maintenance, CIMAvax-EGF, nimotuzumab.

Downloads

Download data is not yet available.

References

Referencias

1. Bradley SH, Kennedy MPT, Neal RD. Recognising Lung Cancer in Primary Care. Adv Ther [Internet]. 2019 [citado 2020 Oct 12];36(1):9-30. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30499068/

2. Siegel RL, Miller KD, Jemal A. Cancer stati

Downloads

Published

2021-06-02

How to Cite

1.
Carballo Torres D, Nenínger Vinageras E, Soriano García JL, Saavedra Hernández D, Viada González C. Survival of patients with advanced non-small-cell lung cancer under maintenance therapy with CIMAvax-EGF or nimotuzumab. Rev Cub Oncol [Internet]. 2021 Jun. 2 [cited 2026 Jan. 13];19(1). Available from: https://revoncologia.sld.cu/index.php/onc/article/view/112

Issue

Vol. 19 No. 1 (2021): enero-abril

Section

Artículos Originales

License

Esta revista provee acceso libre e inmediato a su contenido bajo el principio de que hacer disponible gratuitamente la investigación al público apoya a un mayor intercambio de conocimiento global.

Esto significa que se permite su copia y distribución por cualquier medio siempre que mantenga el reconocimiento de sus autores, no haga uso comercial de las obras y no realice ninguna modificación de ellas.

El envío de manuscritos, el procesamiento y la publicación no ofrece ningún coste a los autores, es totalmente gratis.